The importance of lowering the costs of stem cell transplantation in developing countries
The effectiveness and efficiency of health care systems can be assessed by economic evaluation, comparing the costs and outcomes of alternative interventions. Direct costs include accommodation, nursing, physicians’ fees, diagnostic tests and treatment. Indirect costs derive from the loss of a persons ability to use life in a productive way e.g. employment. In cost-effectiveness analyses, cost is the numerator and effectiveness (related to health outcomes) is the denominator. The unit of measurement of effectiveness is usually years of life saved. Cost utility analyses require a preference-based measurement of health-related quality of life (HRQL) to allow the calculation of utility scores for health states and so the adjustment of effectiveness for quality. Typically, this allows the calculation of qualityadjusted life years (QALYs). A review of published reports, to be presented in detail, yields the following summation. The greater cost of stem cell harvest from peripheral blood is more than offset by the reduced costs associated with a shorter hospital stay. Transplants early in first remission cost less than those undertaken at later points in disease evolution/treatment experience. Changing the primary locus of care from inpatient to outpatient may result in notable cost savings but can produce cost-shifting (from inpatient to outpatient). Nevertheless, in selected patient, the use of non-myeloablative transplants may offer a cost-effective option, especially in the developing country context.
KeywordsAcute Myeloid Leukemia Stem Cell Transplantation Bone Marrow Transplantation Utility Score Peripheral Blood Stem Cell
Unable to display preview. Download preview PDF.
- 3.Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumours and lymphomas: Hematologic recovery and costs. A randomized, controlled trial.Ann Intern. 1997;126:600–607.Google Scholar
- 4.Barr RD, Furlong W, Horsman JR, Feeny D, Torrance GW, Weitzman S. The monetary costs of childhood cancer to the families of patients.Int J Oncol. 1996;8:933–940.Google Scholar
- 5.Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York, Oxford University Press, 1996. pp1–425.Google Scholar
- 7.Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. Baltimore, Williams and Williams, 1996;5:2–6.Google Scholar
- 13.Beard MEJ, Inder AB, Allen JR, Hart DN, Heaton DC, Spearing RL. The costs and benefits of bone marrow transplantation.NZ Med J. 1991;104:303–305.Google Scholar
- 15.Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.Can Med Assoc J. 1992;146:473–481.Google Scholar